ALK inhibitors have shown activity in a range of solid tumors and hematologic malignances and have achieved approval in the rare solid tumor IMT and in the hematologic malignancy ALCL, in addition to the NSCLC approval (Table 1)28–34,36–39 and (Table 4)35,48,73,74,85,94,126,130–149. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.